Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed SARS-CoV-2 infection within 5 days prior to randomization
Initial onset of COVID-19 signs/symptoms within 5 days prior to the day of randomization and at least 1 of the specified COVID-19 signs/symptoms present on the day of randomization
Fertile participants must agree to use a highly effective method of contraception
Has at least 1 characteristic or underlying medical condition associated with an increased risk of developing severe illness from COVID-19
You may not be if
History of or need for hospitalization for the medical treatment of COVID-19
Prior to current disease episode, any confirmed SARS-CoV-2 infection
Known medical history of active liver disease
Receiving dialysis or have known moderate to severe renal impairment
Known human immunodeficiency virus (HIV) infection with a viral load greater than 400 copies/mL or taking prohibited medications for HIV treatment
Suspected or confirmed concurrent active systemic infection other than COVID-19
History of hypersensitivity or other contraindication to any of the components of the study intervention
Current or expected use of any medications or substances that are highly dependent on CYP3A4 for clearance or are strong inducers of CYP3A4
Has received or is expected to receive convalescent COVID-19 plasma
Has received or is expected to receive any dose of a SARS-CoV-2 vaccine before the Day 34 visit
Participating in another interventional clinical study with an investigational compound or device, including those for COVID-19 through the long-term follow-up visit
Known prior participation in this trial or other trial involving PF-07321332
Oxygen saturation of \<92% on room air, or on their standard home oxygen supplementation for those who regularly receive chronic supplementary oxygen for an underlying lung condition
